Cardiomyopathy is caused by functional abnormality of cardiac muscle. The functional abnormality involved in its etiology includes both extrinsic and intrinsic factors, and cardiomyopathy caused by the intrinsic factors is called as idiopathic or primary cardiomyopathy. There are several clinical types of primary cardiomyopathy including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). Linkage studies and candidate gene approaches have explored the disease genes for hereditary primary cardiomyopathy. The most notable finding was that mutations in the same disease gene can be found in different clinical types of cardiomyopathy. Functional analyses of disease-related mutations have revealed that characteristic functional alterations are associated with the clinical types, such that increased and decreased Ca 2+ sensitivity due to sarcomere mutations are associated with HCM and DCM, respectively. In addition, our recent studies have suggested that mutations in the Z-disc components found in HCM and DCM may result in increased and decreased stiffness of sarcomere; that is, stiff sarcomere and loose sarcomere, respectively, and hence altered stretch response. More recently, mutations in the components of I region were found in hereditary cardiomyopathy and the functional analyses of the mutations suggested that the altered stress response was associated with cardiomyopathy, further complicating the etiology and pathogenesis. However, elucidation of genetic etiology and functional alterations caused by the mutations shed lights on the new therapeutic approaches to hereditary cardiomyopathy, such that treatment of DCM with a Ca 2+ sensitizer prevented the disease in a mouse model.
INTRODUCTION
Cardiomyopathy is a heterogeneous disease caused by functional abnormality of cardiac muscle and classified into primary cardiomyopathy and secondary cardiomyopathy. 1 Secondary cardiomyopathy is defined as cardiomyopathy caused by extrinsic factors including ischemia, hypertension and metabolic disorders. On the other hand, diagnosis of primary cardiomyopathy is based on the exclusion of secondary cardiomyopathy and there are several different clinical types. 2, 3 Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are two major clinical types of primary cardiomyopathy that had been defined as 'idiopathic'; that is, of unknown etiology. HCM, a major cause of sudden death in young and heart failure, is characterized by left ventricular hypertrophy, often asymmetric, accompanied by myofibrillar disarrays and reduced compliance (diastolic dysfunction) of cardiac ventricles. In contrast, DCM is characterized by dilated ventricular cavity with systolic dysfunction. Clinical symptom of DCM is heart failure and often associated with sudden death. There are other clinical types of cardiomyopathy.
Restrictive cardiomyopathy (RCM) is accompanied by increased stiffness of the myocardium with diastolic dysfunction without significant hypertrophy. 4 In addition, arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by a dilated dysfunctional right ventricle (RV), ventricular arrhythmias and fibrofatty replacement of the RV. Another cardiomyopathy is left ventricular noncompaction (LVNC) characterized by less trabeculations in the left ventricle (LV), as well as LV hypertrophy and/or dilation. 1 The etiology of primary cardiomyopathy had been unknown, but various genetic abnormalities associated with the cardiomyopathy have been unraveled in the past two decades. More than half of HCM patients have family history of the disease consistent with autosomal dominant genetic trait. 5 In the case of DCM, about 20-35% patients had family history of the disease, mainly consistent with the autosomal dominant inheritance, although some familial cases can be explained by autosomal recessive or X-linked recessive trait. 6, 7 Familial occurrence is also noted in RCM, ARVC and LVNC. [1] [2] [3] [4] As the presence of family history suggested the genetic etiology of the disease, linkage studies in multiplex families were taken to identify the disease loci in each family. Identification of the disease loci has enabled one to decipher the disease-linked mutations in the genes located within the loci. Subsequently, other candidate gene analyses, focused on the genes encoding for proteins related or interacting with products of the disease genes, have been successful in unraveling novel disease genes. As shown in Table 1 many different disease genes were identified. The most important point is the overlapping of disease genes for different clinical types.
SARCOMERE MUTATIONS IN HCM
Identification of a missense mutation in cardiac b-myosin heavy chain gene (MYH7) linked to HCM in a large multiplex family was the first demonstration of the disease gene for HCM. 8 Subsequently, many investigators have analyzed MYH7 for mutations in HCM patients and many different missense mutations were identified as the cause. However, frequency of MYH7 mutations in the patients was less than half and there were many families not linked to the MYH7 locus. Linkage studies in such non-MYH7-linked HCM families have revealed mutations in a-tropomyosin gene (TPM1), cardiac troponin T gene (TNNT2) and cardiac myosin binding protein-C gene (MYBP3) as the causes of HCM. As these genes encode for components of sarcomere involved in muscle contraction, genes for other sarcomere components were analyzed and lead to the identification of HCM-associated mutations in ventricular myosin essential light chain gene (MYL3), ventricular myosin regulatory light chain gene (MYL2), cardiac troponin I gene (TNNI3), cardiac a-actin (CACT) and cardiac troponin C (TNNC1). Therefore, mutations in any components of sarcomere can result in HCM. 3, 5 Our study has showed that sarcomere mutations are found in about 40% of East Asian (Japanese and Korean) patients with familial HCM in the heterozygous state, consistent with the autosomal dominant inheritance (Table 2) . About 20, 10 and 10% of patients carried mutations in MYH7, TNNT2 and MYBPC3, respectively, whereas a few cases had mutations in other components of sarcomere such as MYL2, MYL3 and TNNI3. So far investigated, we found no patient who had mutations in two or more disease genes, although there were some patients who were homozygous for the sarcomere mutation. The homozygous patients showed severer clinical manifestations than the heterozygous patients in the family, demonstrating the gene dose of mutation. 9 Disease-related mutations can also be found in sporadic HCM (Table 2) . We found one de novo case, 10 but the other sporadic cases were probably due to the low penetrance of the mutation, because most of the mutations found in the sporadic HCM patients can also be found in other patients with familial HCM.
The most striking impact of unraveling disease genes and diseasecausing mutations is not only that the etiology and pathogenesis of cardiomyopathy are understood but also that the genetic testing will be at least in part available for the cardiomyopathy. The genetic testing is useful for the provision of prognosis and more specifically predicting risk for unfavorable outcome such as sudden cardiac death or heart failure. From the beginning of unraveling disease-causing mutations, genotype-phenotype correlation analyses was one of the main focus and such analyses were mainly reported for HCM. Clinical manifestations of HCM due to the sarcomere mutations were in general different from each other, but there were some tendencies of genotype-phenotype correlations. 11, 12 For example, Watkins et al. 13 hypothesized that the MYH7 mutations leading to amino acid changes with charge alteration was associated with poor survival prognosis. However, it is not simply applicable to all the MYH7 mutations. As shown in Figure 1 , three different MYH7 mutations, Arg249Gln, Gly716Arg and Asp778Gly, with poor survival prognosis 14, 15 were all categorized into charge altered mutation. On the other hand, there were three other different MYH7 mutations, Arg143Gln, Arg870His and Arg870Cys, with relatively benign survival prognosis 16, 17 and two of them, Arg143Gln and Arg870Cys, were also associated with charge alteration. As Arg249Gln, Gly716Arg and Asp778Gly were mapped within the functionally important domain of myosin heavy chain, 
ATP-binding domain, converter domain and myosin light chaininteracting domain, 18 respectively, while the benign mutations Arg143Gln and Arg870Cys were not mapped within these important domains. As the mutations reported by Watkins et al. 13 were all mapped within the ATP-binding domain, actin-interacting domain, converter domain or myosin light chain-interacting domains, 18 it was speculated that the mutations with charge alteration and mapped within the functionally important domains were correlated with poor survival prognosis.
In addition, there were several interesting characteristics of mutation-prone HCM patients in East Asians (Japanese and Korean), such that cardiac hypertrophy was more prominent in MYH7 and MYBPC3 cases than TNNT2 cases (Table 3) . It may be worth noting that the age at diagnosis was relatively late and cardiac function at the diagnosis was relatively lowered in TNNT2 cases than the others. 10 This was in good agreement with that TNNT2 mutations are generally associated with poor prognosis and sudden cardiac death in European populations. 19, 20 Although MYBPC3 cases were initially reported to follow relatively benign clinical course in an European population, 21 our data showed that 36% of MYBPC3 cases in East Asians followed worse prognosis during the follow-up period (Table 3 ). In general, cardiac hypertrophy developed at the diagnosis gradually reduced during the follow-up period, and cardiac function becomes decreased later in the life even in the MYBPC3 cases. 22 Initial analysis of functional changes caused by the MYH7 mutations demonstrated decreased power generation by the mutant myosin heavy chains 23 and the identification of HCM-related mutations in sarcomere components, troponin T and a-tropomyosin, had lead to a hypothesis that HCM is the disease of sarcomere and the cardiac hypertrophy was a compensation of decreased power generation. 24 However, we found HCM-associated TNNI3 mutations at the contraction inhibitory domain, 10 which implied that the decreased power was not a common functional change caused by the sarcomere mutations. Indeed, subsequent functional analyses of mutations in genes for other sarcomere components than MTH7 have revealed that contractile performance was not decreased by the mutations and most HCM-associated sarcomere mutations resulted in increased Ca 2+ sensitivity of muscle contraction. [25] [26] [27] [28] [29] [30] As an MYH7 mutation that caused HCM in transgenic mice also increased Ca 2+ sensitivity at the muscle fiber level, 31 a common functional alteration caused by HCMrelated sarcomere mutations may be the increased Ca 2+ sensitivity. Muscle contraction is regulated by the concentration of intracellular Ca 2+ that is released from sarcoplasmic reticulum (SR) via ryanodine receptor (RyR2) and re-up taken to SR via SR Ca 2+ -ATPase (SERCA). When the concentration of Ca 2+ is increased or decreased, muscle is contracted or relaxed, respectively. Increased Ca 2+ sensitivity is a leftward shift of Ca 2+ -tension curve; more tension is generated by mutant sarcomere than normal sarcomere at the same Ca 2+ concentration (hypercontraction) or muscle with mutant sarcomere is under less relax states (diastolic dysfunction) than normal sarcomere. This is consistent with the finding that characteristic features of HCM are hypercontraction and diastolic dysfunction.
Z-DISC MUTATIONS IN HCM
As mutations in the sarcomere components were found in only less than half of familial HCM patients, there should be other disease gene(s) for HCM, and candidate gene approaches were taken to identify the disease-related mutations in other genes expressed in cardiac muscle (Figure 2 ). Identification of an HCM-associated mutation in titin gene (TTN) was the first example of disease gene other than the sarcomere components, 32 and the functional alteration due to the TTN mutation was an increased binding to a-actinin (Figure 3) . In addition, we demonstrated that the HCM-associated Tcap gene (TCAP) mutations increased the binding of Tcap to titin, MLP and carsarcin-1, 33 leading to a hypothesis that Z-disc mutations in HCM may result in increased binding of Z-disc components and hence 'stiff sarcomere' (Figure 3) . 'Stiff sarcomere' would increase passive tension on stretch of sarcomere. As the increased passive tension was associated with increased Ca 2+ sensitivity, [34] [35] [36] we have speculated that HCM-associated abnormality in both Z-disc components and sarcomere components cause the increased Ca 2+ sensitivity. It should be noted that a possible controversy exists; that is, HCMassociated MLP gene (CSRP3) mutations were reported to decrease the binding to a-actinin and N-RAP. 37, 38 However, as discussed in the later section, DCM-associated mutations were found in CSRP3 and a-actinin gene (ACTN2), and these mutations decreased binding to each other. 39 Therefore, the decreased binding between MLP and aactinin was associated with both HCM and DCM. This discrepancy should be resolved by further studies.
OTHER MUTATIONS IN HCM
There are several other disease genes for HCM, including mutations in caveolin-3 gene (CAV3), 40 meta-vinculin gene (VCL), 41 aB-crystallin gene (CRYAB), 42 junctophilin-2 gene (JPH-2), 43 obscurin gene (OBSCN) 44 and most recently reported CARP gene (ANKRD1) 45 ( Figure 2 ). Functional analyses were reported for CRYAB, CAV3, OBSCN and ANKRD1 mutations; aggregation of aB-crystalline in cytoplasm, 42 decreased cell surface expression of caveolin-3, 40 decreased binding to titin, 44 and increased binding to titin and myopalladin, 45 respectively. It is not clear how the aggregated aB-crystalline resulted in cardiac hypertrophy, but impaired stress response may exaggerate hypertrophic response. 46 It should be noted here that an HCM-associated TTN mutation in N2B region increased binding to FHL2 protein 47 and decreased binding to aB-crystalline. 48 As for the function of caveolin-3 in cardiac function, it was reported that cell surface expression of caveolin-3 was associated with cardiac hypertrophy. 49 It was also reported that overexpression of caveolin-3 inhibit the hypertrophic response, 50 suggesting that reduced caveolin-3-mediated signaling would result in cardiac hypertrophy. Function of obscurin is not fully understood, but obscurin may be involved in calmodulin/CaMK-mediated signaling because obscurin was reported to bind and tether calmodulin to titin, 51 of which process was impaired by the HCM-associated OBSCN mutation. The functional significance of increased binding of CARP to titin and myopalladin caused by the ANKRD1 mutations is not clarified, but mutant CARP showed nuclear or peri-nuclear localization, whereas normal CARP was exclusively localized in the cytoplasm. 52 As CARP is a hypertrophy-related transcriptional co-factor 52 and is known to be localized 
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A Kimura in the cytoplasm and shifted to nucleus when cardiomyocytes were stretched, 53 presence of mutant CARP to nucleus suggested that the mutation rendered the cardiomyocytes hypersensitive to the stretch response leading to hypertrophy.
MEMBRANOUS AND CYTOSKELETAL MUTATIONS IN DCM
The first discovery of disease gene for DCM is a mutation in dystrophin gene (DMD) found in male siblings of X-linked DCM. 54 X-linked DCM is a rare form of familial DCM almost exclusively affecting males. 55 DMD mutations are known to cause Duchenne type and Becker type muscular dystrophy. In general, muscular dystrophy mainly affects skeletal muscles, and cardiac involvement is observed usually later in the clinical course. 56, 57 However, X-linked DCM cases usually manifest with cardiac symptoms and subtle skeletal muscle involvement, 55 and phenotypic variance of DMD mutation may be caused by which domain of dystrophin was affected. 56 As shown in Table 4 , our study showed that DMD mutations could be found in 5% of sporadic cases. None of these patients showed skeletal muscle symptoms, demonstrating that X-linked DCM should be considered not only for male sibling of familial DCM but also for male cases of sporadic DCM. Dystrophin is a membranous protein having an important function in mechanical links from extracellular matrix to intracellular cytoskeleton in association with other proteins forming dystroglycan complex (DGC). 58 As muscle contraction forces myocytes with deformity and shortening/stretching, myofilaments should be tightly anchored to membrane and extracellular matrix via DGC to properly transmit the force with avoiding damages of cell membrane. Components of DGC in skeletal and cardiac muscles include dystrophin, dystroglycans (a and b), laminin as, sarcoglycans (a, b, g and d), dystrobrebins (a and b), syntrophin and caveolin-3. In addition to DGC, integrins (a and b) are concentrated at the costemeres that overly Z-lines in striated muscles, and the integrin complex also has a function in mechanical links of power transmission. 58 laminin a4 gene (LMNA4), 60 and integrin-linked kinase gene (ILK) 60 were found to cause DCM of autosomal dominant inheritance (Table 1) . It was proposed that DCM was the disease of cytoskeleton or its interacting proteins. 61 However, recent studies showed that etiology of DCM is not confined to the abnormality of the cytoskeleton-related proteins.
SARCOMERE MUTATIONS IN DCM
Identification of cardiac a-actin gene (CACT) mutations was the first discovery of genetic cause of autosomal dominant DCM. 62 In addition, CACT mutation was also found in HCM, 63 demonstrating that sarcomere mutations cause both HCM and DCM; that is, overlapping disease genes for different cardiomyopathy. Molecular basis of different phenotypes caused by CACT mutations was suggested that DCMassociated mutations were found at the a-actinin-interacting domain, 62 whereas HCM-associated mutations were at the interacting domain to myosin heavy chain. 63 On the other hand, recent data suggested that there is a difference in folding property between the DCM-associated mutant actin and HCM-associated mutant actin. 64 Another example of overlapping disease gene was the identification of TNNT2 mutation in DCM. 65 Functional study of TNNT2 mutations clearly demonstrated the difference between DCM-associated mutation and HCM-associated mutation; that is, DCM-associated TNNT2 mutation decreased Ca 2+ sensitivity of muscle contraction, which is in clear contrast to the increased sensitivity caused by the HCMassociated mutation. 66 Therefore, sarcomere mutations can be found in both HCM and DCM, but difference in the functional alterations may determine the different phenotypes. 67 
Z-DISC MUTATIONS IN DCM
Mutations of membranous, cytoskeletal or sarcomere components were not found in our panel of familial DCM, whereas mutations in Z-disc components were relatively frequent (Table 4) . We have reported several DCM-associated Z-disc protein gene mutations in TTN, 68 CSRP3, 69 TCAP 33,69 and Cypher/ZASP gene (LDB3), 70 albeit that CSRP3 mutation was not found in Japanese or Korean patients. 69 As described in the HCM section, the DCM-associated TCAP mutations showed opposite functional alterations to the HCM-associated mutations. 33 Similarly, a DCM-associated TTN mutation found in the actinin-binding domain showed decreased binding to actinin. 68 In addition, another DCM-associated TTN mutation found in the Tcapbinding domain decreased the binding to Tcap. 68 As the Z-disc element mutations result in decreased binding among the elements, we hypothesize that DCM is the disease of 'loose sarcomere' 12, 33 ( Figure 3) . The loose sarcomere is evident in an animal model of DCM, CSRP3 (MLP) knock-out mouse, in which Z-disc was wide and stretch response was impaired. 69 As the stretch response is a hypertrophic response of cardiomyocytes against passive tension and Z-disc elements is suggested to be a stretch sensor of cardiomyocytes, abnormality in Z-disc elements may alter the regulation of stretch response. Cypher/ZASP is a Z-disc element connecting calsarcin and actinin. 70 It is interesting to note that calsarcin binds calcineurin, 71 a Ser/ Thr phosphatase involved in the process of hypertrophic program of cardiomyocytes. 72, 73 Functional significance of calcineurin anchorage to Z-disc is not fully understood, but it was involved in stress-induced calcineurin-NFAT activation, because heterozygous MLP knock-out mice showed reduction in NFAT activation along with dislocation of calcineurin from Z-disk. 74 On the other hand, Cypher/ZASP binds protein kinase C (PKC) 70 and a DCM-associated LDB3 mutation in the PKC-binding domain was found to increase the binding, 75 it was suggested that phosphorylation/dephosphorylation of Z-disc elements might be involved in the stretch response. Identification of target protein(s) for phosphorylation (by PKC)/dephosphorylation (by calcineurin) will unravel the molecular mechanism(s) of stretch response and/or signaling molecule(s) of cardiac hypertrophy.
Several other LDB 3 mutations not in the PKC-interacting domain were reported in DCM or LVNC. 76 As the functional changes caused by these mutations had not been demonstrated, we have searched for binding protein to Cypher/ZASP by using yeast two-hybrid method, and found that phosphoglucomutase-1 (PGM1) as a novel-binding protein. 77 PGM1 is an enzyme involved in the conversion between glucose-6-phospate and glucose-1-phosphate, which is involved in the glucose/glycogen metabolism. Functional significance of the binding between PGM1 and the Z-disc element Cypher/ZASP was not known, but the DCM-associated mutations reported by Vatta et al. 76 showed decreased binding to PGM1. 77 In addition, PGM1 was demonstrated to be localized at the Z-disc under the stressed culture conditions, low serum and low glucose, suggesting the role of PGM1 in the energy metabolism at the Z-disc. 77 These observations suggested that the decreased stress response might be involved in the pathogenesis of DCM.
There are other DCM-associated mutations found in genes for other Z-line associated proteins, desmin (DES) 78 and metavinculin (VCL). 79 The VCL mutation was showed to impair the binding to actin, 79 whereas the DES mutations resulted in subtle change in the cytoplasmic DES network. 80 In addition, mutations in myopalladin gene (MYPN) have recently been reported in DCM. Although the molecular mechanisms of MYPN mutations leading to DCM remained unclear, the DCM-associated mutations impaired the myofiblinogenesis. 81 
OTHER MUTATIONS IN DCM
Etiology of familial DCM is quite heterogeneous, and there are several other disease genes for DCM categorized into several groups. The first group includes mutations in genes for nuclear membrane proteins, lamin A/C (LMNA) 82, 83 and emerin (EMD), 84 which cause autosomal dominant and X-linked Emery-Dreifuss muscular dystrophy (EDMD), respectively. EDMD manifests with muscular dystrophy and DCM associated with conduction block. 85 Molecular mechanisms underlying the development of DCM caused by the nuclear membrane abnormality remain not fully understood, 86 but a study of an LMNA mutation knock-in mouse 87 showed that the mutation activated the MAPK pathway, suggesting an impaired signal transduction was involved in the pathogenesis of DCM. 88 The second group consists of mutations affecting ion channel function; regulatory subunit of ATP-sensitive potassium channel (ABCC9) 89 and cardiac sodium channel (SCN5A). 90 Clinical phenotypes of ABCC9 and SCN5A mutations were DCM accompanied by ventricular tachyrcardia 89 and conduction defects, 90 respectively. It should be noted here that the channelopathy is etiologically overlapping with the cardiomyopathy, such as SCN5A mutations in DCM and long QT syndrome, CAV3 mutations in HCM and long QT syndrome, and RYR2 mutations in ARVC and catecholaminergic polymorphic ventricular tachycardia. 91 The third group is composed of mutations in genes for titin-N2B-interacting proteins, four and half LIM protein (FHL2) 92 and aBcrystallin (CRYAB). 48 As a titin-N2B region mutation found in DCM reduced binding to FHL2 47 and an FHL2 mutation reduced binding to titin-N2B, 92 impaired interaction between titin and FHL2 appeared as a result in DCM. Molecular mechanisms underlying this phenomenon may be that FHL2 function as a tethering molecule of adenyl kinase, phosphofructokinase and muscle creatine kinase; that is, proper recruitment of metabolic enzymes was impaired, although abnormality in other functions of FHL2 93 could not be neglected. The DCMassociated CRYAB mutation decreased binding to titin-N2B region and a DCM-associated titin-N2B region mutation decreased binding to aB-crystallin, 48 suggesting that impaired interaction between titin-N2B and aB-crystallin resulted in DCM. However, an HCM-associated titin-N2B mutation also reduced the binding to aB-crystallin, 47 and it is not clear why the impaired binding of titin-N2B and aBcrystallin could express as both HCM and DCM. There may be additional factors involved in the phenotypic expression of titin-N2B mutations, such that binding to FHL2 was different between the HCM-and DCM-associated mutations and that the DCMassociated titin-N2B mutation was a truncation mutation, whereas the HCM-associated mutation was a missense mutation. 47 In addition, we found DCM-associated mutations in ANKRD1. 94 The fourth group is related to intracellular Ca 2+ handling. As muscle contraction is depending on the Ca 2+ concentration, SERCA function in re-uptaking the intracellular Ca 2+ to SR leads to relaxation of muscle. Phospolamban is an inhibitory molecule of SERCA, which is physiologically active when phosphorylated by protein kinase A (PKA). 95 Functional analysis of phospholamban gene (PLN) mutations found in DCM showed that the mutation was constitutive active; that is, inhibiting SERCA. 96, 97 In contrast, a truncation mutation of PLN, that is loss of PLN function, is recently reported in familial HCM. 98 Although PLN deficiency in mice resulted in enhanced contractility, 99 no cardiac hypertrophy was observed in the mice. In addition, loss of PLN rescued DCM phenotype 100 in MLP knock-out mice, and a dominant-negative form of PLN prevented heart failure in cardiomyopathic hamster BIO14.6, 101 which is known to be caused by SAGD deficiency. 102 These observations suggest that functional impairment of phospholamban may prevent systolic dysfunction but not directly involved in the cardiac hypertrophy. Moreover, promoter mutations of PLN, which increased transcription, were recently reported in HCM. 103, 104 As transgenic mice over-expressing PLN did not show cardiac hypertrophy, rather they showed systolic dysfunction, 105 pathological significance of PLN promoter mutations in HCM remains to be clarified.
The other mutations found in DCM include G4.5 gene (tafazzin, TAZ, Barth's syndrome), 106 fukutin gene (FKTN), 107 desmoplakin gene (DSP), 108 plakoglobin gene (JUP) 109 mutations. These mutations, however, were not found in 'pure' DCM and found in 'syndromic' DCM that is accompanied by disorders and/or dysfunction in skeletal muscle, skin or hair. An example is that FKTN mutation was not found in pure DCM, but was found in skeletal myopathy accompanied by DCM and an early sign of FKTN mutation-associated DCM was hyper-CKemia. 110 
MUTATIONS IN OTHER CARDIOMYOPATHIES
Disease-causing gene mutations can also be identified in other cardiomyopathies. As shown in Table 1 , mutations in sarcomere proteins were found in RCM. It is interesting to note that MYH7, TNNT2 and TNNI3 mutations were associated with RCM, HCM and DCM. Molecular basis of the differences between RCM-associated mutations and HCM-associated mutations was that the RCM-associated mutations showed much greater Ca 2+ sensitization than the HCM-associated mutations, as demonstrated for TNNT2 111 and TNNI3 112 mutations. In accordance with these findings, it was reported that restrictive phenotype (RCM-like HCM) was uncommon in HCM and may represent a poor prognosis form with severe diastolic dysfunction. 113 On the other hand, the difference between RCM-associated mutations and DCM-associated mutations is not clear, but a gene-dose effect could be involved in the difference because RCM-associated TNNI3 mutation was found in heterozygous state, 114 whereas the DCM-associated TNNI3 mutation was found in homozygous state. 115 LVNC is a recently described cardiomyopathy where ventricular trabeculations was poorly developed, and mutations in MYH7, 116 CACT, 117 DES, 78 LMNA, 118 TAZ, 119 DTNA, 120 and LDB3 76 were reported in LVNC (Table 1 ). Molecular mechanisms of the mutations in causing LVNC are not elucidated. In a mouse model, deficiency of BMP10 resulted in LVNC phenotype. 121 BMP10 is a member of TGFb family, which is expressed mainly in the heart, and has an important function in morphogenesis of the heart. 122 Therefore, LVNC might be a developmental error in the hearts carrying the mutations in components of sarcomere and/or sarcolemma. Interestingly, a rare polymorphism of BMP10 gene was found in hypertensive DCM, which decreased binding to Tcap and increased extracellular secretion of BMP10 facilitating the remodeling of hypertensive hearts. 123 Another primary cardiomyopathy AVRC has also been investigated for disease-causing mutations 124 (Table 1) . As the ARVC-associated mutations can be found in genes for plakoglobin (JUP), 125 desmoplakin (DSP), 126 plakophilin-2 (PKP2) 127 and desmoglein (DSG3), 128 they were considered to disrupt cell-cell contacts via desmosomes. RYR2 mutations were also reported in ARVC, 129 linking cardiomyopathy to channelopathy. Promoter variant of TGFb3 was also reported in ARVC, 130 but its pathological significance remains to be resolved.
CONCLUSION
In this review, gene mutations found in the hereditary cardiomyopathy are summarized. Each family or patient has usually only one disease-causing mutation, but the primary cardiomyopathy is both clinically and etiologically heterogeneous even in a specific clinical type (HCM, DCM, RCM, ARVC and LVNC). As different causes result in the same phenotype, there may be several pathways in the pathogenesis of primary cardiomyopathy, such as abnormalities in the Ca 2+ sensitivity, stretch response, stress response and others. Intervention of these common pathways will be a therapeutic or preventive strategy for hereditary cardiomyopathy caused by different mutations. In this respect, it is noteworthy that administration of a Ca 2+ sensitizing chemical compound SCH00013 131 336, 267-276 (1997).
